Aida Pharmaceuticals
Aida Pharmaceuticals provides update on Rh-Apo2L in lymphoma
Published in Genetics and Environmental Law Weekly, October 7th, 2006
The following are excerpts from the company's update:
Qiaer Biotechnology recently completed phase I trials of the genetic cancer treatment drug Rh-Apo2L. Rh-Apo2L is a new drug therapy using a recombinant protein produced by genetic engineering, called human Apo2L which can cause cell apoptosis - cellular death - by triggering points on the receptors in the cells of tumors. Scientists believe that cancer cells may resist or not activate apoptosis, thus continuing to grow and divide uncontrollably...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Law Weekly
More Articles from Genetics and Environmental Law Weekly
- Affymetrix
Affymetrix selected to genotype more than 9000 Framingham Heart Study samples - Hythiam
European Patent Office grants Hythiam patent for treatment of alcohol dependence - Royal Perth Hospital, Wellington, Australia
Adaptive host-viral relationships crucial in shaping host and pathogen genetic diversity - Universidad de Navarra, Spain
Advanced genetic diagnostic method may mean earlier diagnosis of multiple myeloma - Acacia Research
CombiMatrix announces commercial launch of its first molecular diagnostic test - Alpha Innotech
AlphaScan Microarray Scanner from Alpha Innotech now available from partner - More from this issue of Genetics and Environmental Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
